Riskpilot← Back to searchSign inGet full accessABACUS MEDICINE A/S
A/SActiveCVR 28111576Kalvebod Brygge 35Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2004381 employeeswww.abacusmedicine.com
Revenue 2024
DKK 981,9M
+18% vs 2023
EBITDA margin
3.2%
-8% vs 2023
Equity ratio
30.3%
Financial strength
Net profit 2024
DKK 17,6M
-12% vs 2023
| Revenue | DKK 981,9M | +18% |
| EBITDA | DKK 31,7M | -8% |
| Net profit | DKK 17,6M | -12% |
| Total assets | DKK 316,9M | +11% |
| Equity | DKK 95,9M | +19% |
| Employees | 381 | — |
Legal name
ABACUS MEDICINE A/S
CVR number
28111576
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. september 2004
Share capital
DKK 518.822
Employees
381 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et medlem af direktionen i forening med bestyrelsens formand, af den administrerende direktør i forening med et medlem af direktionen, af et medlem af direktionen i forening med to medlemmer af bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive parallelhandel med lægemidler, handel med medicin vedrørende ikke-registrerede lægemidler og handel med lægemidler i forbindelse med kliniske forsøg samt hermed beslægtet virksomhed.
Address
Kalvebod Brygge 35
Phone
+4570220212
Email
info@abacusmedicine.com
Website
www.abacusmedicine.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 489.457 | 625.228 | 835.482 | 1.320.154 | 253.056 | 332.347 | 421.445 | 558.971 | 671.129 | 675.307 | 832.248 | 981.864 |
| Staff expenses | -15.421 | -23.499 | -26.950 | -45.817 | -12.856 | -18.969 | -24.570 | -15.133 | -15.904 | -22.281 | -29.904 | -34.824 |
| EBITDA | 20.292 | 32.852 | 34.873 | 51.066 | 9.417 | 12.580 | 10.649 | 12.776 | 14.229 | 23.184 | 34.614 | 31.710 |
| Depreciation & amort. | 7.230 | -7.963 | -8.367 | -9.906 | -1.857 | -2.712 | -5.249 | -3.865 | -4.799 | -6.172 | -6.750 | -7.160 |
| EBIT | 13.062 | 24.889 | 26.506 | 41.160 | 7.560 | 9.868 | 5.400 | 8.911 | 9.430 | 17.012 | 27.864 | 24.550 |
| Net financials | -6.344 | -7.165 | -3.694 | -4.193 | -160 | -2.136 | -1.111 | -11.675 | -11.551 | -12.832 | 613 | 998 |
| Profit before tax | 6.718 | 17.724 | 22.812 | 36.967 | 6.132 | 7.350 | 2.577 | 1.533 | 1.974 | 8.543 | 24.812 | 21.987 |
| Tax | 1.065 | 4.500 | 4.997 | 8.312 | 1.804 | 1.991 | 1.748 | 1.100 | 1.559 | 2.724 | 4.770 | 4.366 |
| Net profit | 5.653 | 13.224 | 17.815 | 28.655 | 4.328 | 5.359 | 829 | 433 | 415 | 5.819 | 20.042 | 17.621 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 74.113 | 93.125 | 179.823 | 250.896 | 55.204 | 96.037 | 126.357 | 166.712 | 172.684 | 179.901 | 285.817 | 316.854 |
| Equity | 6.122 | 24.402 | 61.663 | 70.680 | 9.671 | 14.399 | 51.616 | 53.024 | 54.646 | 60.991 | 80.866 | 95.895 |
| Long-term debt | 0 | 20.000 | 0 | 0 | 2.053 | 1.892 | 3.797 | 4.712 | 10.158 | 9.025 | 5.750 | 4.109 |
| Short-term debt | 66.784 | 44.238 | 112.474 | 173.217 | 42.919 | 77.585 | 66.701 | 102.968 | 103.746 | 105.628 | 193.813 | 210.523 |
| Total debt | 66.784 | 64.238 | 112.474 | 173.217 | 44.972 | 79.477 | 70.498 | 107.680 | 113.904 | 114.653 | 199.563 | 214.632 |
EBITDA margin
3.2%
This company
15.8%
Market median
-80% vs market
20132024
Equity ratio
30.3%
This company
38.2%
Market median
+21% vs market
20132024
Return on equity
18.4%
This company
18.4%
Market median
+0% vs market
20132024
Net profit margin
1.8%
This company
8.1%
Market median
-78% vs market
20132024
Asset turnover
3.10×
This company
1.12×
Market median
+177% vs market
20132024
Debt / equity
2.30×
This company
0.62×
Market median
-271% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FW Chief Executive Officer | Chief Executive Officer | 2009 | — | — |
PV Founder | Founder | 2004 | — | — |
JW Management | Management | 2004 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Wagner Family Holding ApS | Company | 50.0% | 50.0% | 2019 |
CHR. AUGUSTINUS FABRIKKER AKTIESELSKAB | Company | 33.3% | 33.3% | 2019 |
Thorsen Ejendomme A/S | Company | 25.0% | 25.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AUGUSTINUS FONDEN
ABACUS MEDICINE A/S Board members of ABACUS MEDICINE A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Flemming Wagner | Chief Executive Officer | 0 companies |
| Per Villendrup Jenster | Founder | 0 companies |
| John Wagner | Management | 0 companies |
| Iwan Alstrup | Board of Directors | 0 companies |
| Sharon Evelyn Curran | Board of Directors | 0 companies |
| Mark Johnston | Board of Directors | 0 companies |
| Anders Kunze Bønding | Board of Directors | 0 companies |
| Michala Fischer-Hansen | Board of Directors | 0 companies |
| Ole Jensen | Board of Directors | 0 companies |
| Alette Margaretha Verbeek | Board of Directors | 0 companies |
| Jytte Birgitte Wagner | Board of Directors | 0 companies |
| Lars Aaen | Board of Directors | 0 companies |
| Niels Smedegaard | Chairman | 0 companies |
| Jens Albert Harsaae | Chairman | 0 companies |
| Troels Peter Troelsen | Board of Directors | 0 companies |
| Lars Christian Bruhn | Chairman | 0 companies |
| Bo Michael Palm | Board of Directors | 0 companies |